Caris Life Sciences CAI
NASDAQ CAI
$31.50 -0.05 (-0.16%)
As of: Sep 30, 2026 · 1:25 PM EDT

Caris Life Sciences, Inc. (CAI) EBITDA Margin (2024 - 2026)

Updated

Caris Life Sciences' EBITDA Margin came in at 12.68% for Q2 2026, up 19.06 percentage points from -6.39% a year earlier and up 7.87 percentage points from the prior quarter.

Analysis

Caris Life Sciences, Inc. (CAI) EBITDA Margin (2024 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Caris Life Sciences reported EBITDA Margin of 17.59%, up 43.97 percentage points year-over-year; for FY2025, it was 8.34%, up 58.84 percentage points from FY2024.

  • Going back by year, EBITDA Margin was -50.50% in FY2024 (+37.87 pp) and -88.38% in FY2023.
  • The five-year range for quarterly EBITDA Margin is -55.38% (Q2 2024) to 31.65% (Q4 2025).
  • Year-over-year, EBITDA Margin has increased for five consecutive quarters, with an average year-over-year change of +47.00 percentage points over the last five quarters.
  • Business Quant data shows CAI's EBITDA Margin at 4.80% (Q1 2026), 31.65% (Q4 2025) and 17.31% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 12.68%
Mar 31, 2026 4.80%
Dec 31, 2025 31.65%
Sep 30, 2025 17.31%
Jun 30, 2025 -6.39%
Mar 31, 2025 -42.10%
Dec 31, 2024 -21.54%
Sep 30, 2024 -49.54%
Jun 30, 2024 -55.38%
API Access

Caris Life Sciences, Inc. EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CAI&period=max&api_key=YOUR_API_KEY